The ABCB8 Knockout Jurkat Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population derived from Jurkat T lymphocytes, with targeted disruption of the ABCB8 gene. This pool of knockout cells retains genetic diversity and provides a versatile loss-of-function model for studying ABCB8-dependent mitochondrial processes without clonal artifacts. The polyclonal format reflects heterogeneous gene disruption across the population, suitable for robust phenotypic analyses in a suspension cell context.
The Jurkat cell line is a human T-cell acute lymphoblastic leukemia suspension line, originally from a 14-year-old male, and is widely employed for dissecting T-cell receptor signaling, apoptosis, and immune function. Its rapid proliferation and ease of manipulation make it a workhorse in immunological and cancer research, enabling detailed biochemical and genetic studies. This host offers a leukemia-relevant background for investigating mitochondrial biology in T cells.
ABCB8 is a mitochondrial ABC transporter crucial for heme export to the cytosol, thereby regulating iron homeostasis, heme biosynthesis, and oxidative stress defense. The protein interacts with ferrochelatase, mitoferrins, frataxin, and ISCU to couple iron utilization with heme and iron-sulfur cluster production. ABCB8 expression is controlled by PGC-1??, IRP1/IRP2, and hypoxia-inducible factors, and it functions alongside related transporters ABCB7 and ABCB10. Knockout of ABCB8 disrupts mitochondrial heme export, leading to iron accumulation, impaired heme synthesis, and elevated mitochondrial reactive oxygen species, as heme incorporation into hemoproteins and iron-sulfur cluster assembly are compromised.
In Jurkat T cells, ABCB8 knockout creates a relevant model for probing mitochondrial iron handling and oxidative stress in leukemic T-cell biology. The disruption exacerbates redox imbalance and mitochondrial dysfunction, which can influence T-cell receptor signaling, apoptosis, and drug sensitivity. This model is valuable for dissecting how impaired heme export contributes to mitochondrial toxicity and cardiac-related drug side effects, connecting metabolic stress to malignant T-cell survival.
This cell product is suited for investigating iron metabolism, mitochondrial dysfunction, drug-induced cardiotoxicity, and T-cell apoptosis. Common assays include Western blotting and qRT-PCR for gene disruption verification, mitochondrial iron quantification, ROS detection, heme synthesis measurement, apoptosis and viability assays, and flow cytometry for mitochondrial membrane potential. Drug sensitivity screening can be performed to evaluate compounds targeting mitochondrial iron pathways. For additional details or assay customization, please contact Ascent Research.
